CClinicalTrials.gg
Status unknownNCT03622853Updated Aug 9, 2018

What Factors Area Associated With Prognosis After Steroid Hydrodilatation for Adhesive Capsulitis

An interventional study of Steroid (shincort) in Adhesive Capsulitis, sponsored by Taipei Veterans General Hospital, Taiwan. Status unknown at 1 site in Taiwan. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
35 Years to 65 Years
Sex
All
01

Study summary

To investigate the factors associated with improvement after intraarticular steroid injection for patients with Frozen shoulder

Read the detailed description

Objective: To investigate the factors associated with improvement after intraarticular steroid injection for patients with Frozen shoulder

Design: Prospective study.

Participants: Patients with Frozen shoulder were recorded the demographic data, associated disease, ultrasound findings at baselines.

Intervention: One shot intraarticular steroid hydrodilatation

Main Outcome Measures: Visual analog scale (VAS) of the shoulder pain, Constant score, SPADI score, and angles of active and passive shoulder range of motion (flexion, abduction, external rotation, and internal rotation) at pre-treatment, post-treatment at week 8

02

Conditions studied

  • Adhesive Capsulitis

Browse trials for

Keywords

  • adhesive capsulitis
03

In context

Bursitis

411 studies on the registry are indexed under Bursitis; 112 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 371 interventional studies indexed under Bursitis.

Browse Bursitis studies →

Lead sponsor

Taipei Veterans General Hospital, Taiwan is the lead sponsor of 325 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of frozen shoulder by physical examination and ultrasonography

Exclusion criteria

Exclusion Criteria:

  1. other conditions involving the shoulder ( rheumatoid arthritis, Hill-Sachs lesions,osteoporosis, or malignancies in the shoulder region);
  2. neurologic deficits affecting shoulder function in normal daily activities;
  3. shoulder pain caused by cervical radiculopathy
  4. a history of drug allergy to xylocaine
  5. pregnancy or lactation;
  6. received injection into the affected shoulder during the preceding 3 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    intraarticular steroid injection

    intraarticular steroid hydrodilatation (shincort 40mg )

    Drug: Steroid (shincort)

Interventions

  • DrugSteroid (shincort)

    intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline

    Also known as: shincort

06

What researchers measure

Primary outcomes

  1. The change of constant shoulder score between week 0 and week 8

    the total constant score ranges from 0 to 100 points, with higher scores indicative of better function. The score is divided into four sections: pain, activity of daily living, ROM and strength

    Time frame: 0 and 8 wks

Secondary outcomes

  1. pain intensity

    pain intensity was measured by visual analog scale. Each patient was asked to indicate his/her current level of pain by marking a point on a 100-mm VAS, for which 0 represented no pain and 100 represented unbearable pain.

    Time frame: 0 and 8 wks

  2. Shoulder Pain And disability index

    The Shoulder Pain and Disability Index (SPADI) is a self-administered questionnaire that consists of two dimensions, one for pain and the other for functional activities. The pain dimension consists of five questions regarding the severity of an individual's pain. Functional activities are assessed with eight questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use. The SPADI takes 5 to 10 minutes for a patient to complete and is the only reliable and valid region-specific measure for the shoulder.

    Time frame: 0 and 8 wks

  3. glenohumeral joint range of motion

    Shoulder flexion, abduction, external rotation and internal rotation were measured with goniometer with patient in supine position

    Time frame: 0 and 8 wks

07

Study locations

1 of 1 sites recruiting
  • Taipei Veterans General Hospital
    Taipei, 241, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03622853
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Jan 1, 2018
Primary completion
Mar 1, 2019 (estimated)
Completion
Mar 1, 2019 (estimated)
Last update
Aug 9, 2018

Study contacts

Jia chi c Wang, MD
Contact
jcwang0726@gmail.com
919527693

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion